Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment

Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment

Monoclonal AntibodiesWhat Are Monoclonal Antibodies?

A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders.


Growing Interest for Monoclonal Antibody Therapies

Monoclonal antibodies were initially used to treat advanced cancers that hadn’t responded to chemotherapy or cancers that had returned despite treatment. However, because these treatments have proved to be effective, certain monoclonal antibody treatments are being used earlier in the course of the disease. This has sparked incredible growth in the manufacturing and supply of new mAbs, and has provided much promising news for many cancer patients.


Monoclonal Antibody Supply

Proper manufacturing is complex and a constant supply is valuable. Due to the complex nature of mAbs and their inherent heterogeneity, careful attention is required for product design and manufacturing to assure a safe, effective and consistent supply of these products to you and your company.

Currently LGM Pharma supplies these cutting edge mAbs for cancer research, and has the following sample quantities for your R&D purposes:

  • Trastuzumab CAS# 180288-69-1 – Some of the most aggressive breast cancers (approx. 25{ea91ce937acfcedac5cfadbb01091089b0d0efaf901d2d8d1bf3570326cfc2cb} of primary breast cancers) are driven by overly expressed HER2 receptors – which cause the rapid progression of breast cancer. Trastuzumab targets these receptors both intercellularly (by inhibiting cell proliferation) and extracellularly (by flagging them for destruction by the immune system), effectively leading to HER2 positive tumor cell stasis and death. In addition, based on preclinical studies, Trastuzumab enhances the effects of chemotherapy. Read more about Trastuzumab here: Higher survival rates for Trastuzumab in combination with chemotherapy in advanced gastroesophageal junction cancer.
  • Abciximab CAS# 143653-53-6Abciximab is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Abciximab is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
  • Cetuximab CAS# 205923-56-4Cetuximab is an approved treatment for metastatic colorectal cancer and locally advanced squamous cell carcinoma of the head and neck. Cetuximab is designed to seek out and lock onto a protein called epidermal growth factor receptor (EGFR), which is located on certain cells in the body. Some cancers have higher than normal numbers of these receptors on their surfaces. Once Cetuximab attaches to these cells, it brings in other immune cells to help kill them.
  • Rituximab CAS# 174722-31-7Rituximab attaches to a specific protein (CD20) found only on B cells, one type of white blood cell. Certain types of lymphomas arise from these same B cells. When Rituximab attaches to this protein on the B cells, it makes the cells more visible to the immune system, which can then attack. Rituximab lowers the number of B cells, including your healthy B cells, but your body produces new healthy B cells to replace these. The cancerous B cells are less likely to recur. Rituximab can be used as an initial treatment in some types of non-Hodgkin’s lymphoma.
  • Ofatumumab, CAS# 679818-59-8, 769818-59-8
  • Panitumumab, CAS# 339177-26-3

Future mAb Product Supply

Currently LGM Pharma has several new mAbs under development. Lab samples of the following mAbs will soon be available:

Learn more

LGM Pharma is not only a supplier of rare research molecules, but they are also a solutions provider that solves your needs. Search through our monoclonal antibodies, or contact LGM Pharma to assist you in your future endeavors.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service